PCM
TVTX icon

Prelude Capital Management’s Travere Therapeutics TVTX Stock Holding History

Prelude Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,599
Closed -$787K – 1597
2025
Q4 		$787K Sell
20,599
-25,808
-56% -$839K 0.06% 380
2025
Q3 		$1.11M Sell
46,407
-2,650
-5% -$49.8K 0.09% 290
2025
Q2 		$726K Buy
49,057
+13,148
+37% +$218K 0.07% 344
2025
Q1 		$643K Buy
+35,909
New +$729K 0.05% 432
2024
Q3 		– Sell
-107,222
Closed -$881K – 1552
2024
Q2 		$881K Buy
107,222
+24,800
+30% +$167K 0.06% 345
2024
Q1 		$635K Buy
82,422
+54,000
+190% +$456K 0.03% 531
2023
Q4 		$256K Buy
+28,422
New +$207K 0.02% 826
2021
Q1 		– Sell
-79,528
Closed -$2.17M – 1821
2020
Q4 		$2.17M Sell
79,528
-55,552
-41% -$1.3M 0.06% 277
2020
Q3 		$2.49M Buy
+135,080
New +$2.63M 0.12% 117
2020
Q1 		– Sell
-800
Closed -$11K – 2047
2019
Q4 		$11K Buy
+800
New +$10.2K ﹤0.01% 1692
2018
Q4 		– Sell
-5,287
Closed -$152K – 2167
2018
Q3 		$152K Buy
5,287
+1,787
+51% +$51.1K 0.01% 850
2018
Q2 		$95K Buy
3,500
+500
+17% +$13.3K 0.01% 941
2018
Q1 		$67K Buy
+3,000
New +$71.4K ﹤0.01% 983
2016
Q4 		– Sell
-11,245
Closed -$252K – 1784
2016
Q3 		$252K Buy
11,245
+5,766
+105% +$110K 0.03% 495
2016
Q2 		$98K Buy
5,479
+995
+22% +$16.1K 0.01% 772
2016
Q1 		$61K Buy
4,484
+984
+28% +$14.9K 0.01% 929
2015
Q4 		$68K Buy
3,500
+764
+28% +$15.3K 0.01% 952
2015
Q3 		$55K Buy
2,736
+1,736
+174% +$51.4K 0.01% 1036
2015
Q2 		$33K Buy
+1,000
New +$27.4K ﹤0.01% 1257

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's TVTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 20,599 shares — an estimated $787K sold.

Prelude Capital Management first reported a position in TVTX in Q2 2015 and held it in 19 quarters. The position peaked at $2.49M in Q3 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Prelude Capital Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 20,599 Travere Therapeutics shares in Q1 2026, an estimated $787K.
  • Prelude Capital Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 19 quarters.
  • Prelude Capital Management's Travere Therapeutics position peaked at $2.49M in Q3 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.